Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

451
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
451
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

509
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
509
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

496
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
496
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

370
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
370
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

545
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
545
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

332
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.

International urology and nephrology·2026
Same author

Increasing Left Ventricular Mass and Death in Men and Women Investigated With Echocardiography.

Journal of the American Heart Association·2025
Same author

Rationale for and design of the REsolution of LEft VENTricular thrombus (RELEVENT) Trial.

American heart journal·2025
Same author

Differentiating Anderson-Fabry Disease from Other Causes of Left Ventricular Hypertrophy: Novel Insights from Left Atrial Strain Imaging.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2025
Same author

Functional coronary angiogram findings in angina with non-obstructive coronary arteries patients with coronary slow flow.

American heart journal·2025
Same author

Characterization of the Left Ventricular Myocardium in Systemic Sclerosis.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Jan 25, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K

Mavacamten in Obstructive Hypertrophic Cardiomyopathy-A First Australian Experience.

Antony Chun Fai So1, Kathryn A Davison2, Teresa Hecker3

  • 1Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, SA, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia; Cardiac Imaging Research, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.

Heart, Lung & Circulation
|January 23, 2026
PubMed
Summary

Mavacamten significantly reduced obstructive hypertrophic cardiomyopathy (oHCM) symptoms and left ventricular outflow tract (LVOT) gradients in Australian patients. The cardiac myosin inhibitor demonstrated a tolerable safety profile over 24 weeks.

Keywords:
Left ventricular ejection fractionLeft ventricular global longitudinal strainLeft ventricular outflow tract gradientMavacamtenNew York Heart Association classObstructive hypertrophic cardiomyopathy

More Related Videos

Lipidico Injection Protocol for Serial Crystallography Measurements at the Australian Synchrotron
07:28

Lipidico Injection Protocol for Serial Crystallography Measurements at the Australian Synchrotron

Published on: September 23, 2020

3.6K
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

7.1K

Related Experiment Videos

Last Updated: Jan 25, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Lipidico Injection Protocol for Serial Crystallography Measurements at the Australian Synchrotron
07:28

Lipidico Injection Protocol for Serial Crystallography Measurements at the Australian Synchrotron

Published on: September 23, 2020

3.6K
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

7.1K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Mavacamten, a novel cardiac myosin inhibitor, is approved in Australia for obstructive hypertrophic cardiomyopathy (oHCM).
  • International studies confirm mavacamten's efficacy, but real-world Australian data were lacking.
  • This study addresses the need for Australian real-world data on mavacamten's impact and safety.

Purpose of the Study:

  • To evaluate the real-world effectiveness of mavacamten in Australian patients with symptomatic oHCM.
  • To assess the safety and tolerability of mavacamten in this cohort.
  • To analyze changes in hemodynamic and functional parameters over 24 weeks.

Main Methods:

  • A single-centre observational study of 23 symptomatic oHCM patients treated with mavacamten.
  • Assessment of baseline and 24-week echocardiographic parameters (LVOT gradients, LVEF, LV global longitudinal function) and NYHA class.
  • Monitoring of treatment-emergent adverse events and patient adherence.

Main Results:

  • Mavacamten significantly reduced resting (56 to 16 mmHg) and Valsalva (92 to 37 mmHg) LVOT gradients (p<0.001).
  • 70% of patients showed at least one NYHA class improvement, with high adherence (99%).
  • A tolerable safety profile was observed, with 13% discontinuing treatment due to adverse events.

Conclusions:

  • Mavacamten provides significant clinical and echocardiographic benefits in Australian oHCM patients.
  • The drug demonstrates a tolerable safety profile within the first 6 months of use.
  • This study offers valuable real-world Australian data on mavacamten therapy.